Anti-DR6 antibodies and methods of immune regulation
AssigneeNational University Corporation Hokkaido University
InventorsDaisuke Fujikura, Toshimitsu Uede
Life of this patent
Estimating the term…
Loading patent…
AssigneeNational University Corporation Hokkaido University
InventorsDaisuke Fujikura, Toshimitsu Uede
Estimating the term…
The problems: It is an object of the present invention to provide an immune regulating agent capable of modulating a receptor function concerning immune regulation of DR6, and a method for screening thereof. The object aims to provide: The present invention relates to an immune regulating agent containing a physiologically active substance having an ability to bind specifically to DR6 and an ability to regulate signal transduction induced by specific binding between DR6 and Sdc1, as an active component. The immune regulating agent of the present invention can be used for treating or preventing diseases caused by excessive or abnormal immune response in mammals or diseases for which enhancement of immune function is desired in mammals, as an immune regulating agent based on a hitherto unknown mechanism, capable of regulating signal transduction induced by specific binding between DR6 and Sdc1.
A method for regulating IL-2 production by T cells expressing Death Receptor 6 in a mammal, comprising administering to the mammal an effective amount of a physiologically active substance,
A method for suppressing proliferation of CD4+ T cells expressing Death Receptor 6 in a mammal, comprising administering to the mammal an effective amount of a physiologically active substance,
A method for treating systemic lupus erythematosus (SLE) in a mammal, comprising administering to the mammal an effective amount of an anti-Death Receptor 6 antibody, wherein the antibody comprises a heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO:
Dependencies are inferred from the claim text.